Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triac Trial II in young children with MCT8 deficiency
NL-OMON60742Phase 2Active, not recruiting
- Sponsor
- Egetis Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tiratricol in Allan-Herndon-Dudley syndrome (AHDS) (2 arms), sponsored by Egetis Therapeutics. Primary endpoints: GMFM-88 total score at week 96, BSID-III Gross Motor Skill Domain at week 96 and 2 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on NL-OMON60742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60742.